RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Studies in patients with type 2 diabetes are needed to further assess and allow comparison of several GLP-1RA agents' impact on steady-state pharmacokinetics and pharmacodynamics of concomitant ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

Glucagon-like peptide 1 receptor agonists (GLP-1RA) are transforming the treatment of obesity and type 2 diabetes. As an approach to optimize efficacy and minimize side effects, co-agonists ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

If a person decides to start GLP-1RA treatment, careful monitoring is essential to quickly identify any worsening of eating disorder behaviors, such as the development of extreme dietary ...

Semaglutide, a weekly GLP-1RA, has shown promising results in multiple trials. For example, a 72-week phase II trial involving 320 patients with MASH, reported MASH resolution rates of up to 59% ...

The most notable decrease in obesity was in the South, the study says, noting that that’s the area with “the highest observed per capita GLP-1RA dispensing rate.” Steve Christo/Corbis/Corbis ...

Type 2 diabetes is a chronic condition that affects the body’s ability to regulate blood sugar levels. For many patients, ...

“The most notable decrease was in the South, which had the highest observed per capita GLP-1RA dispensing rate.” One author ...